Health Care International - ERBITUX Data Demonstrate Improvements In Response Rate And Progression-Free Survival In Wild Type K-Ras Metastatic Colorectal Cancer Patients
ImClone Systems Incorporated (NASDAQ: IMCL) today announced data from the Phase II OPUS study that show that the addition of ERBITUX® (cetuximab) to FOLFOX chemotherapy significantly improves both response rate and progression-free survival over FOL
Comments